Improving the safety of systemic viral gene therapy.
作者信息
McNally Elizabeth M
出版信息
J Clin Invest. 2024 Jan 2;134(1):e177078. doi: 10.1172/JCI177078.
Abstract
摘要
相似文献
1
Improving the safety of systemic viral gene therapy.
J Clin Invest. 2024 Jan 2;134(1):e177078. doi: 10.1172/JCI177078.
2
Improving safety of gene therapy.
Curr Drug Saf. 2008 Jan;3(1):46-53. doi: 10.2174/157488608783333925.
3
Biosafety of viral vectors commonly used in gene therapy and vaccination.
Curr Gene Ther. 2013 Dec;13(6):383-4. doi: 10.2174/156652321306140103215705.
4
Gene therapy for hemophilia: are viral vectors really feasible?
J Thromb Haemost. 2003 Feb;1(2):218-9. doi: 10.1046/j.1538-7836.2003.00095.x.
5
Viral vector-mediated transgenic cell therapy in regenerative medicine: safety of the process.
Expert Opin Biol Ther. 2015 Apr;15(4):559-67. doi: 10.1517/14712598.2015.995086. Epub 2014 Dec 20.
6
Retrovirus-induced oncogenesis and safety of retroviral vectors.
Curr Opin Mol Ther. 2008 Oct;10(5):431-8.
7
Safety aspects of gene therapy.
Br J Haematol. 1992 Apr;80(4):421-6. doi: 10.1111/j.1365-2141.1992.tb04552.x.
8
Severe Toxicity in Nonhuman Primates and Piglets with Systemic High-Dose Administration of Adeno-Associated Virus Serotype 9-Like Vectors: Putting Patients First.
Hum Gene Ther. 2018 Mar;29(3):283-284. doi: 10.1089/hum.2018.021. Epub 2018 Feb 7.
9
Lentiviral vectors derived from simian immunodeficiency virus.
Curr Top Microbiol Immunol. 2002;261:53-74. doi: 10.1007/978-3-642-56114-6_3.
10
Principles of safety, efficacy and stability in gene therapy--review.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Jun;12(3):392-6.
引用本文的文献
1
Dominantly inherited muscle disorders: understanding their complexity and exploring therapeutic approaches.
Dis Model Mech. 2024 Oct 1;17(10). doi: 10.1242/dmm.050720. Epub 2024 Nov 6.
2
Advancements and Innovations in the Surgical Management of Sacrococcygeal Pilonidal Sinus: A Comprehensive Review.
Cureus. 2024 May 26;16(5):e61141. doi: 10.7759/cureus.61141. eCollection 2024 May.
3
Targeting arrhythmogenic macrophages: lessons learned from arrhythmogenic cardiomyopathy.
J Clin Invest. 2024 May 15;134(10):e180482. doi: 10.1172/JCI180482.
本文引用的文献
1
Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies.
J Clin Invest. 2024 Jan 2;134(1):e173510. doi: 10.1172/JCI173510.
2
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.
N Engl J Med. 2023 Sep 28;389(13):1203-1210. doi: 10.1056/NEJMoa2307798.
3
Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy.
N Engl J Med. 2023 Jun 15;388(24):2294-2296. doi: 10.1056/NEJMc2212912.
4
Meeting Report: 2022 Muscular Dystrophy Association Summit on 'Safety and Challenges in Gene Transfer Therapy'.
J Neuromuscul Dis. 2023;10(3):327-336. doi: 10.3233/JND-221639.
Zotero 插件